BBG Advanced Therapies, a subsidiary of San Antonio-based nonprofit BioBridge Global, today announced a collaboration ...

New preliminary clinical data presented at ISSCR 2026 evaluated an induced pluripotent stem cell (iPSC)-derived CAR T-cell ...

Fate Therapeutics has seen improvements in 4 patients with treatment-resistant systemic sclerosis who were dosed with it | ...

Outpatient monitoring of CAR T-cell therapy reduces healthcare resource utilization and hospital days without impacting 30-day mortality, finds ASCO study.

A new form of CAR T cell therapy has been designed to find and destroy the cancer-driving stem cells responsible for a group of blood cancers known as myeloproliferative neoplasms (MPNs), while ...

Researchers at the University of Pittsburgh, UPMC Hillman Cancer Center and the National Cancer Institute report that ...

Summary: Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized the treatment of liquid blood cancers by engineering a patient’s own immune cells to destroy malignant targets, replicating ...

Building on recent successes, scientists are focused on a promising new frontier: sending tiny particles into the body to ...

Before starting cell therapy, patients need more than hope — they need a plan. Dr. Muhammad Tariq breaks down what to expect ...

Today at ISSCR 2026, new preliminary clinical data was presented evaluating an induced pluripotent stem cell (iPSC)-derived ...

U.S. pharmaceutical company Moderna announced on the 26th (local time) that it will begin developing an “in vivo CAR-T” ...

CAR T-cell therapy is expected to expand quickly across autoimmune skin diseases following an anticipated regulatory approval that might come as soon as this year.